Stock data
| Market cap. | SEK463.4m |
| Last close | SEK5.06 |
| High / Low (52 weeks) | SEK5.6 / SEK2.1 |
| Stock market listing | US |
| Forecast net cash (SEKm) | 19.2 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (2.1) | 105.7 | 22.4 |
| Relative * | (4.8) | 102.8 | 15.5 |
* % Relative to local index
Other companies in sector Show
Company news
Investment summary
NeuroVive Pharmaceutical is a mitochondrial medicine specialist. NeuroVive’s core portfolio targets orphan indications: traumatic brain injury with NeuroSTAT, various genetic mitochondrial diseases with KL1333 and NVP015, and mitochondrial myopathy with NVP025. Following the positive outcome in a Phase IIa study with NeuroSTAT, the drug candidate will proceed to a proof-of-concept study. The second most advanced product KL1333, in-licensed from Yungjin Pharm in May 2017, demonstrated positive results in the Phase I trial in South Korea. Recent highlight is an out-licensing of a subset of compounds from NVP015 program for localized treatment of LHON to BridgeBio Pharma for a deal value of around $60m. Other products for out-licensing include NV556 and NVP022 for NASH and NVP024 for hepatocellular carcinoma.
Last updated on 27/07/2018
| Y/E Dec | Revenue (SEKm) | EBITDA (SEKm) | PBT (SEKm) | EPS (öre) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 0.0 | (69.9) | (70.7) | (172.27) | N/A | N/A |
| 2017A | 0.6 | (67.9) | (70.1) | (149.31) | N/A | N/A |
| 2018E | 0.6 | (83.5) | (83.6) | (132.64) | N/A | N/A |
| 2019E | 0.6 | (132.0) | (132.2) | (170.66) | N/A | N/A |
Last updated on 13/07/2018
Latest research
KL1333 Ph I positive; rights issue oversubscribed
Update | Pharmaceutical & healthcare | 04/06/2018
Rights issue to reach several R&D events
Update | Pharmaceutical & healthcare | 05/03/2018
Two new trials and likely out-licensing in 2018
Update | Pharmaceutical & healthcare | 14/12/2017
R&D progress on track; new investor on board
Update | Pharmaceutical & healthcare | 25/08/2017
Mitochondrial medicine specialist
Initiation | Pharmaceutical & healthcare | 29/06/2017
Latest video
Industry outlook
NeuroVive has a diversified portfolio with all assets aimed at improving mitochondrial metabolism and function. This puts NeuroVive among the very few experts in mitochondrial medicine in the industry, in our view. Central to NeuroVive’s strategy is maintaining a network of KOLs, academic institutions and research organisations, which help to run innovative design and cost-effective studies.
Last updated on 27/07/2018
Key management
| Erik Kinnman, CEO |
| Catharina Jz Johansson, CFO |
| Magnus Hansson , Chief Medical Officer |
| Daniel Schale, Director of Communications |
Company address
| Medicon Village Scheelevägen 2, Lund SE-223 81 Sweden 46 4 62 75 62 20 View website |